Labiana Health Past Earnings Performance
Past criteria checks 0/6
Labiana Health's earnings have been declining at an average annual rate of -79.5%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 0.07% per year.
Key information
-79.5%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 5.0% |
| Revenue growth rate | -0.07% |
| Return on equity | -206.2% |
| Net Margin | -15.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Labiana Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 60 | -10 | 28 | 0 |
| 31 Mar 23 | 60 | -9 | 28 | 0 |
| 31 Dec 22 | 61 | -9 | 28 | 0 |
| 31 Dec 21 | 59 | -2 | 27 | 0 |
Quality Earnings: LAB is currently unprofitable.
Growing Profit Margin: LAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LAB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LAB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.8%).
Return on Equity
High ROE: LAB has a negative Return on Equity (-206.15%), as it is currently unprofitable.